The monitoring of antiaggregation effect of XXXX therapy by measuring serum @entity7489 in @entity1 with coronary artery bypass grafting.

@entity1 @entity117 @entity7489 @entity1031 @entity583 @entity7943
UNASSIGNED: Cardiovascular @entity1 take @entity117 ( @entity7943 ) for preventing @entity583 and other @entity1031 . It is already known that in some @entity1 this therapy is not effective. The aim of this study was to assess the percentage of @entity7943 resistance on the sample of @entity1 with coronary artery bypass grafting. Our study included 105 @entity1 with coronary artery bypass grafting treated with @entity7943 150mg/day or lesser. Platelet aggregation was measured by serum @entity7489 level as well as impedance aggregometry from whole blood to determine @entity7943 antiaggregation effect. The percentage of @entity7943 resistance was 41.9% with impedance aggregometry, and after determining the serum @entity7489 level this percentage was only 8.6%. The correlation between these two methods was weak (r=0.443; P<0.0001). @entity1031 complications still occur in @entity7943 -treated @entity1 because some @entity1 are resistant to @entity7943 therapy. It would be useful to monitor the effectiveness of @entity7943 therapy and give another antiaggregation drug to these @entity1 to reduce adverse events. The problem is which test is ideal because different tests show different percentages of @entity7943 resistance.
